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Abstract
Background—In order to investigate the role of non-surgical treatment for early-stage
esophageal cancer, we compared the outcomes of local therapy to esophagectomy using a large,
national database.
Methods—Five-year cancer-specific and overall survival of patients with T1N0M0 squamous
cell or adenocarcinoma of the mid or distal esophagus treated with either surgery or local therapy
with ablative and/or excision techniques in the SEER cancer registry from 1998–2008 were
compared using the Kaplan-Meier approach and multivariable and propensity score adjusted Cox
proportional-hazard and competing risk models.
Results—Of 1458 patients with T1N0 esophageal cancer, 1204 (83%) had surgery and 254
(17%) had local therapy only. The use of local therapy increased significantly from 8.1% in 1998
to 24.1% in 2008 (p<0.001). The 5-year overall survival after local excisional therapy and surgery
was not significantly different (55.5% vs 64.1% respectively, p=0.07); 5-year cancer-specific
survival also did not differ (81.7% vs 75.8%, p=0.10). However, after propensity-score
adjustment, cancer-specific survival was better for patients undergoing local therapy compared to
surgery (HR: 0.46, 95% CI: 0.27–0.77, p=0.003), while overall survival remained similar.
Conclusion—The use of local therapy for T1N0 esophageal cancers increased significantly from
1998 to 2008. Compared to esophagectomy, patients treated with local therapy had similar overall
survival but improved cancer specific survival, indicating a higher chance of dying from other
causes. Further studies are needed to confirm the oncologic efficacy of local therapy when used in
patients whose lifespans are not limited by conditions other than esophageal cancer.
Introduction
The prognosis for patients treated for intra- and submucosal esophageal cancers is
significantly better than the prognosis for all other patients found to have esophageal cancer,
even those also found in other relatively early-stage disease [1]. Historically, esophagectomy
has been demonstrated to be oncologically efficacious; however, despite improvement over
time, surgery is still associated with considerable morbidity and mortality [2–8]. Local
treatments with modalities such as endoscopic mucosal resection, radiofrequency ablation,
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cryotherapy, and photodynamic therapy have shown potential for providing effective cancer
treatment with much less treatment-related morbidity [9–20]. However, most reports related
to these therapies involve relatively small clinical trials or single-institution retrospective
reviews with limited long term follow up. We sought to investigate treatment trends of local
therapy use for T1N0 esophageal cancer using the population-based, national Surveillance
Epidemiology and End Results (SEER) cancer registry. To evaluate the efficacy of local
therapy compared to esophagectomy, we also sought to test the hypothesis that patients with
stage T1N0M0 esophageal cancer in the SEER database from 1998–2008 who underwent
esophagectomy had improved survival compared to patients that had local therapy.
Methods
Approval was obtained from the Duke University Institutional Review Board prior to
conducting this retrospective cohort analysis using SEER data for patients from 1998 to
2008. SEER*Stat 7.0.5 was used to extract patients 18 years or older with cancer of the mid
or lower esophagus. Patients were primarily identified through the “SEER Site Recode”
using the term “esophagus”. The variable “Histologic Type ICD-O-3″ (International
classifications of Diseases for Oncology, 3rd edition) was used to restrict the study cohort to
patients with either squamous cell cancer (codes 8050-8089) or adenocarcinomas (codes
8140-8389). To restrict the cohort to patients with T1N0M0 tumors, the tumor-node-
metastasis (TNM) stage was either directly extracted from the SEER database or manually
recoded using available SEER variables. The 6th edition of the AJCC Cancer Staging
Manual served as the basis for this recoding [21]. Patients with unknown or other TNM
stages were excluded from the analysis.
The primary outcome was 5-year cancer specific (CSS) and overall survival (OS), measured
in months. Patients alive at the last available follow-up date in SEER were right censored at
this date in the survival analysis. The following additional patient characteristics were
extracted from the dataset: age, gender, race (White, Black, other/unknown), marital status
(married, other/unknown), and cause of death (alive, esophagus, other cause of death). In
addition, data on tumor grade (well/moderate, poor/undifferentiated, unknown), tumor
location (mid or distal esophagus), and histology (adenocarcinoma, squamous cell) were
collected. Based on treatment information available in SEER, we defined two distinct
treatment groups: esophagectomy and local therapy. All other patients were excluded from
the analysis.
Detailed information on the depth of invasion of T1 tumors was recorded starting in 2004,
which allowed further stratification of T1 tumors into those that did not invade the
submucosa (T1a) and those that invaded the submucosa (T1b), according to the newer, 7th
edition of the AJCC Cancer Staging System [22]. Because the risk of lymph node metastases
increases to 26% when the submucosa is involved, local therapy with endoscopic mucosal
resection as curative intent has been proposed as indicated for T1 tumors that do not invade
the submucosa [9, 23, 24]. Therefore, subgroup survival analyses were performed for
patients with T1a tumors.
Statistical analysis
Comparisons of patient characteristics among the two treatment groups were performed
using chi-square test for categorical (frequency, percentages) and two-sample, unpaired t-
test for continuous variables (mean, standard deviations). To assess early versus late
treatment among patients undergoing local therapy, patients were grouped in two time-
periods; early from 1998–2003 and late from 2004–2008. To compare treatment trends over
time between patients undergoing esophagectomy and patients undergoing local therapy,
multivariable adjusted logistic regression models were calculated while year of operation
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was the main predictor. Adjustment was performed for gender, age at diagnosis, race,
marital status, tumor grade, tumor localization, radiation therapy use, and histology.
Cancer specific survival (CSS) was defined by a cause of death from esophageal etiology
while patients dying from another cause were treated as competing risk and patients alive
were right censored. Meanwhile, overall survival (OS) included all deaths from any cause in
the follow-up period while patients alive were right censored. Because staging in patients
with local tumor destruction cannot be assessed with pathological examination, those
patients were excluded from the survival analysis so clinical over-staging or under-staging
in these patients would not bias survival results. To compare CSS and OS among the
treatment groups, survival curves were initially constructed according to the Kaplan-Meier
approach and compared using the log-rank test. Subsequently, unadjusted, multivariable,
and propensity-score adjusted Cox proportional hazard models for OS and competing-risks
regression models for CSS were calculated. Results are presented as hazard ratios (HR) and
95% confidence intervals (CI). Adjustment in the survival analyses was performed for the
following covariates: gender, age, race, marital status, tumor grade, tumor location,
histology, and year of diagnosis (five groups). The propensity score was calculated based on
a logistic regression model where esophagectomy and local therapy were representing the
outcome while the following characteristics were used as covariates in the propensity score
calculation: gender, age, race, marital status, tumor grade (unknowns were included as
additional category), tumor location, histology, and year of diagnosis (five groups). In the
propensity score adjusted survival models, the propensity score representing receipt of
esophagectomy or local therapy was added as an additional potential confounder. To
account for immortal time bias in regard of receipt of esophagectomy and radiation therapy
after diagnosis, we performed two sets of landmark studies in the survival analyses by left
truncating patients who survived less than 3 or 6 months [25]. These additional analyses
allow to further decrease selection bias by excluding patients with short-term adverse
perioperative mortality or for life limiting comorbidities.
All statistical analyses were performed using STATA/SE version 11.2 (Stata Corporation,
College Station, TX, USA) and R version 2.15.1 (R Foundation for Statistical Computing,
Vienna, Austria), the significance level alpha was set at 0.05 and two-sided p-values were
calculated for all analyses.
Results
A total of 1458 patients with T1N0M0 esophageal cancer of the mid and lower esophagus
were identified in the SEER cancer registry during the study period from 1998 to 2008: Of
these, 1204 (83%) were treated with surgery and 254 (17%) had local therapy only. Detailed
patient and tumor characteristics stratified by treatment group are presented in table 1.
Compared to patients undergoing surgery, patients treated with local therapy were
significantly older, more likely to be female, more likely to have a mid esophageal cancer,
and less likely to also have received radiation therapy. Table 2 shows the specific types of
local therapy utilized. A modality that involved local tumor excision was most commonly
used.
There was a significant increase in local treatment use from 8.1% in 1998 to 24.1% in 2008
(Figure 1). This trend held true after multivariable adjustment with an odds ratio of 1.18 per
year (CI: 1.11–1.25, p<0.001). No difference was found for patient and tumor characteristics
comparing patients undergoing local therapy during the early and late time period (data not
shown).
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The results of survival analysis comparing esophagectomy with local excisional therapy are
shown in table 3 and figure 2. Median follow-up was 34 months for surgery and 21 months
for local excisional therapy (p<0.001), while mean follow-up was 40.5 months for surgery
and 27.3 months for local excisional therapy (p<0.001). For all patients, 5-year OS was 63.2
% (95% CI: 60.0–66.3) and 5-year CSS was 76.5% (CI: 73.5–79.2). 5-year OS after local
excisional therapy and surgery was not significantly different [55.5% (CI: 44.0–65.6) vs
64.1% (CI: 60.7–67.3), p=0.07] as was 5-year CSS [81.7% (CI: 70.2–89.1) vs 75.8% (CI:
72.6–78.7), p=0.10]. However, although local excisional therapy did not predict any
statistically significant difference in overall survival compared to surgery in both
multivariable (HR: 0.85, CI: 0.63–1.15, p=0.29) and propensity score (HR: 0.88, CI: 0.64–
1.20, p=0.42) adjustment, local excisional therapy did predict improved CSS compared to
surgery in both multivariable (HR: 0.46, CI: 0.28–0.76, p=0.002) and propensity score
adjusted survival analyses (HR: 0.46, CI: 0.27–0.77, p=0.003).
The short-term OS after esophagectomy was similar to local excisional therapy at 1 month
[esophagectomy 98.6% (CI: 97.7–99.1) vs local excisional therapy 99.5% (CI: 96.7–99.9)],
3 months [esophagectomy 96.9% (CI: 95.7–97.7) vs local excisional therapy 98.0% (CI:
94.9–99.3)] and 6 months [esophagectomy 92.9% (CI: 91.2–94.2) vs local excisional
therapy 93.4% (CI: 88.9–96.1)], p>0.26 for all comparisons. To address potential immortal
bias in the survival analyses and to compare long-term outcomes of esophagectomy and
local excisional therapy when short-term, presumably treatment and comorbidity-related,
mortality is excluded, landmark studies for CSS and OS were performed by applying 3 and
6 month left truncation to survival times (Table 4). These landmark studies showed similar
findings to the non-landmark survival analysis. Patients treated with local therapy continued
to have better CSS in both the three and six month truncated studies, while OS was not
different between the local excisional therapy and esophagectomy patients.
Subgroup analysis for patients with T1a tumor stage
Among patients diagnosed from 2004 to 2008, information about T1a and T1b tumor stage
was available for 764 patients (82.8%). Of those, 436 (57.1%) patients had a T1a esophageal
cancer while 302 (69.3%) patients underwent esophagectomy and 134 (30.7%) patients local
therapy. Among patients with T1b tumor stage (n=328, 42.9%), 296 (90.2%) patients
underwent surgery and 32 (9.8%) patients local therapy. Among T1a and T1b patients, 15
(3.4%) and 5 (1.5%) patients underwent local tumor destruction, respectively, which were
excluded from survival analysis. For patients with T1a tumors, survival for esophagectomy
(2-year CSS: 92.3%, CI: 88.1–95.1; 2-year OS: 86.1, CI: 81.0–89.8) and local excisional
therapy (2-year CSS: 92.6%, CI: 84.0–96.6; 2-year OS: 84.9, CI: 75.7–90.8) did not differ,
even after multivariable (HR for CSS: 0.55, CI: 0.25–1.21, p=0.14; HR for OS: 1.01, CI:
0.57–1.81, p=0.96) and propensity score adjustment (HR for CSS: 0.56, CI: 0.27–1.19,
p=0.13; HR for OS: 1.02, CI: 0.56–1.85, p=0.94) (Figure 3a). Kaplan-Meier survival curves
for patients with T1b tumors are shown in Figure 3b, although similar comparative survival
analyses were not performed due to the small numbers (n=27) of T1b tumors treated with
local excisional therapy.
Discussion
In this study using the SEER database, which is the largest United States population based
cancer registry, we found that local therapy was increasingly utilized for the treatment of
T1N0M0 esophageal cancer over the time period 1998–2008, with a concomitant decrease
in the use of esophagectomy. Overall survival after local therapy was similar to overall
survival after esophagectomy, including short-term follow-up of 1 month, 3 months, and 6
months after diagnosis. However, patients treated with local therapy had better cancer-
specific survival. These results are encouraging and support the promise of utilizing local
Berry et al. Page 4
J Thorac Oncol. Author manuscript; available in PMC 2014 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
therapy as an effective oncologic treatment in patients with early-stage esophageal cancer.
Considering the recovery and potential morbidity associated with the alternative treatment of
esophagectomy, local therapy is a very attractive therapeutic option. However, some caution
is needed before generalizing these results as support that all patients with superficial
esophageal cancer should be treated with local therapy. The fact that patients treated with
local therapy have similar overall survival but better cancer-specific survival than patients
undergoing esophageal resection demonstrates that patients treated with local therapy are
dying from causes other than esophageal cancer at a much higher rate than patients treated
with esophagectomy. Although data recorded by SEER does not allow evaluation of
comorbidities other than demonstrating that patients treated with local therapy were
significantly older than the patients who underwent esophagectomy, many patients selected
to receive local therapy likely had significant other medical conditions that were more
immediately life-threatening than early-stage esophageal cancer and also may have made
them medically ineligible for surgery. This possibility is supported by the observation that
one month, three month, and six month survival after local therapy appears quite similar to
that seen after esophagectomy, despite local therapies being generally thought to have less
procedure-related mortality. This possibility is also further supported by the landmark
analysis. Given that the results of the survival comparison between treatment modalities did
not change in the landmark analysis with both three and six month truncation, the effects on
survival on what would be expected to be increased peri-treatment mortality in the
esophagectomy group appear to be offset from presumably non-procedure related mortality
in the local therapy group.
Therefore, although results after local therapy appear similar to esophagectomy in this study,
continued investigation is necessary before being able to conclude that oncologic outcomes
are truly similar between the two approaches. The patients treated with local therapy in this
study may have been dying of other causes before residual or recurrent esophageal cancer
could occur or lead to mortality. Studies of local therapy with longer follow-up and younger
patients who are not likely to have short-term deaths from other medical conditions are
needed to truly demonstrate that local therapy does not have a higher rate of disease
recurrence compared to esophagectomy. Further observational studies and perhaps even a
multi-institutional randomized controlled trial are recommended to confirm the oncologic
efficacy of local therapy. Until then, patients treated with local therapy should have close
surveillance to evaluate for treatment failures and disease recurrence.
Despite the high mortality typically associated with esophagectomy, overall survival after
esophageal cancer diagnosis at 1 month, 3 months, and 6 months after esophagectomy in
this study was 98.6%, 96.9%, and 92.9%. These corresponding mortality rates of 1.4%,
3.1%, and 7.1% are generally better than those seen in multi-institutional studies or
registries, and more inline with results reported by specialized centers [3–5,8]. Data from
this study does not allow investigation into the reason for this lower than expected mortality.
A possible explanation for this finding is that esophagectomy for early stage disease when
there is not bulky tumor that increases the difficulty of resection and where patients are less
likely to have been given induction therapy have significantly better results than when
surgery is performed for more advanced tumors. Even if mortality is not significantly
different in this study, it is important to acknowledge that esophagectomy likely has
significantly higher peri-treatment morbidity than local therapy. In addition, esophagectomy
may be associated with lifelong alterations in eating habits. To some patients, these potential
short-term and long-term impacts on lifestyle may be worth the trade-off of potentially
slightly higher disease recurrence rates.
Given that our data suggests that local treatment is at least not inferior to surgery, the use of
local therapy may continue to increase for several reasons. First, the techniques of both local
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resection and local tissue destruction may improve and allow more patients to be adequately
treated with these modalities. Second, the increasing percentage of older patients in society
may result in more patients being found to have early-stage esophageal cancer but also
considered marginal candidates for esophageal resection. Third, the encouraging results
associated with local therapy may lead to its increased use in younger and healthier patients,
who also would be considered good surgical candidates. However, the costs associated with
long-term surveillance must be considered when local therapy is progressively used for
younger and healthier patients.
Advantages to the use of SEER data for this analysis include its population based nature,
with volume sufficient to enable subgroup analysis. However, SEER does also have some
inherent limitations. First, data regarding chemotherapy administration are lacking.
However, chemotherapy is not recommended for this stage of esophageal cancer [24], and
so this limitation is not likely significant in this study. However, the exact influence of
chemotherapy in this patient cohort cannot be evaluated. Second, as described above, there
is a lack of data regarding patient co-morbidities that allow specific evaluation on the
importance of co-morbidities on both treatment selection and survival. While propensity
score adjusted analysis does account for the conditional probability of getting either surgery
or local therapy, its power for controlling this selection bias is limited to the covariates
available in the dataset.
In addition, because SEER does not contain detailed enough information about tumor stage
to classify all patients to T1a and T1b tumors, we were limited to the broader tumor stage of
T1 tumors in the main analysis. Patients with T1b tumors are recognized as being
inappropriate candidates for local therapy as a curative intent, so the likely inclusion of at
least some patients who had T1b tumors in the main analysis could bias the results seen with
local therapy [9,23,24]. However, no survival benefit for either treatment was found in the
time-limited subgroup analysis of patients with T1a tumors, further supporting the promise
of local therapy as an equivalent oncologic treatment to esophagectomy. Also, early two-
year cancer-specific survival for esophagectomy and local excisional therapy for patients
with T1a tumors in the later years of the study (2004–2008) was not different. This finding
suggests that local therapies may have been used more often in the later time period for
patients who did not have significant co-morbidities that put them at risk of early death due
to causes other than esophageal cancer. Further, the small number of patients with T1b
tumors undergoing local excisional therapy in the subgroup analysis limits evaluation of the
impact of tumor depth on the main analysis. Selection bias in treatment of T1b tumors may
at least partially explain the difference seen for CSS for T1a tumors versus T1 tumors
overall. Part of the selection bias may have arisen from the preferential use of local therapy
for T1b tumors that were felt to be lower risk of recurring based on the more specific depth
of submucosal invasion (sm1, sm2, sm3), which is not recorded in SEER. Given that local
therapy is considered inadequate for T1b tumors due to high risk of lymph node
involvement, the use of local therapy rather than surgery in these patients also may have
been because the patients were not adequate surgical candidates due to high risk of death
due to other significant co-morbid conditions. Indeed, none of the patients treated with local
therapy for T1b tumors in the SEER dataset died for esophageal cancer reasons despite an
overall 3-year survival of less than 75% (Figure 3b), further supporting selection bias of
local therapy for T1b tumors in patients who were likely to have short-term death from
something other than esophageal cancer. However, future studies including larger groups
stratified for T1a and T1b including information on comorbidities with 5-year follow-up are
warranted.
In conclusion, the use of local therapy for early stage superficial esophageal cancers in the
SEER database has increased significantly over the time period from 1998 to 2008. Overall
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survival after esophagectomy and local therapy was similar, though patients treated with
local therapy had shorter overall follow-up and were more likely to die from causes other
than esophageal cancer. The ability to generalize the results found in this study to other
patients who may not have comorbidities associated with significant short-term mortality is
not clear. Further studies most likely including multi-institutional prospective randomized
controlled trials as well as observational studies with longer follow-up are needed to
determine if local therapy can be utilized with similar long-term oncologic outcomes to
esophagectomy in all patients.
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Figure 1. Change of utilization of esophagectomy and local therapy from 1998 to 2008
Straight line: esophagectomy. Discontinuous line: local therapy. Multivariable adjusted p for
trend < 0.001 (OR per year: 1.18, 95% CI: 1.11–1.25)
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Figure 2. 5-year cancer specific and overall survival comparing esophagectomy and local
therapy
Number of patients at risk at time 0 (esophagectomy: n=1,204; local therapy: n=254). Log
rank test for cancer specific survival: p=0.10, for overall survival: p=0.07.
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Figure 3.
Figure 3a. Cancer-specific and overall survival comparing esophagectomy and local therapy
in T1a tumor subgroups
Number of patients at risk at time 0 (esophagectomy: n=302; local therapy: n=119). Log
rank test for cancer specific survival: p=0.93, for overall survival: p=0.31.
Figure 3b. Cancer-specific and overall survival comparing esophagectomy and local therapy
in T1b tumor subgroups
Number of patients at risk at time 0 (esophagectomy: n=296; local therapy: n=27). Log rank
test for cancer specific survival: p=0.07, for overall survival: p=0.80.
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Table 1
Patient characteristics
Esophagectomy (n=1204) Local Therapy (n=254) p-value
Age (mean, SD), years 64.4 (10.0) 73.4 (9.7) <0.001
Female 190 (15.8%) 60 (23.6%) 0.003
Race
 White 1,111 (92.3%) 240 (94.5%) 0.17
 Black 45 (3.7%) 10 (3.9%)
 Other/Unknown 48 (4.0%) 4 (1.6%)
Marital Status
 Married 850 (70.6%) 164 (64.6%) 0.06
 Other/Unknown 354 (29.4%) 90 (35.4%)
Tumor location
 Mid esophagus 199 (16.5%) 56 (22.1%) 0.04
 Lower esophagus 1,005 (83.5%) 198 (78.0%)
Tumor grade
 G1/2 (well/moderate) 649 (53.9%) 105 (41.3%) <0.001
 G3/4 (poor/undifferentiated) 342 (28.4%) 41 (16.1%)
 Unknown 213 (17.7%) 108 (42.5%)
Histology
 Squamous cell carcinoma 220 (18.3%) 38 (15.0%) 0.21
 Adenocarcinoma 984 (81.7%) 216 (85.0%)
Radiation therapy
 No radiotherapy 957 (79.5%) 217 (85.4%) 0.02
 Beam radiotherapy 242 (20.1%) 34 (13.4%)
 Unknown 5 (0.4%) 3 (1.2%)
Cause of death
 Alive 831 (69.0%) 179 (70.5%) <0.001
 Esophagus 228 (18.9%) 27 (10.6%)
 Other cause of death 145 (12.0%) 48 (18.9%)
Time period
 Early (1998–2003) 487 (40.4%) 48 (18.9%) <0.001
 Late (2004–2008) 717 (59.6%) 206 (81.1%)
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Table 2
Distribution of Local Therapies
Procedure Overall; n (%) Early (1998–2003); n (%) Late (2004–2008); n (%)
Local tumor destruction
 Photodynamic therapy 22 (8.7) 8 (16.7) 14 (6.8)
 Electrocautery 2 (0.8) 0 2 (1.0)
 Cryosurgery 4 (1.6) 0 4 (1.9)
 Laser 8 (3.2) 2 (4.2) 6 (2.9)
 NOS 2 (0.8) 0 2 (1.0)
Local tumor excision
 Polypectomy 23 (9.1) 3 (6.3) 20 (9.7)
 Excisional biopsy 96 (37.8) 19 (39.6) 77 (37.4)
 Laser excision 2 (0.8) 0 2 (1.0)
 NOS 51 (20.1) 6 (12.5) 45 (21.8)
Combined local tumor destruction and excision 44 (17.3) 10 (20.8) 34 (16.5)
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